ClinicalTrials.gg
RecruitingNCT06832306STARIUpdated Aug 6, 2026

STimulation to Activate RespIration

An interventional study of Phrenic Nerve Stimulation in ARDS (Moderate or Severe), AHRF and Mechanically Ventilated ICU Patients, sponsored by Lungpacer Medical Inc.. Recruiting at 7 sites in 2 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-08-06.

Sponsored by Lungpacer Medical Inc. · Not applicable, Interventional, and Treatment

How we know

From the registry’s dates

  • Started May 2025; still recruiting 1 year 5 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
30
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 1,187 studies in Lymphoma, Follicular with a site in United States — 128 open to participants now, 217 under way, 20 of them phase 3. Lymphoma, Follicular · United States.

Planned enrollment
589th of 1,017
30 · median 38
Started
2025
with 30 others
No phase
119 of 1,187
18 open now
Primary completion
2026-09
later than 54 of 216 live
Registered
1,147th of 1,187
by date

Among the 1,187 studies in Lymphoma, Follicular with a site in United States, this one is the 589th largest by planned enrollment of the 1,017 interventional ones that give a count, is one of 31 that started in 2025, is one of 119 with no phase, reaches primary completion later than 54 of the 216 other live ones, and was the 1,147th registered.

Lymphoma, Follicular

1,893 studies on the registry are indexed under Lymphoma, Follicular; 289 are open to participants now.

Browse Lymphoma, Follicular studies →

Open to participants now

128 of the 1,187 studies in Lymphoma, Follicular with a site in United States are open now. Recruiting first, the newest first:

123 more — sign in →

All 128 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 226 Lymphoma, Follicular studies recruiting now, 158 (70%) set no upper age limit and 39 (17%) stop at 75 or younger; 34 take children under 18; 23 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 1,187 studies in Lymphoma, Follicular with a site in United States, or all of them as a file.
02

Study summary

Multi-center, randomized, controlled, open-label Phase 2 feasibility trial. Subjects on mechanical ventilation (MV) for acute hypoxemic respiratory failure (AHRF) with lung injury (including subjects who meet criteria for acute respiratory distress syndrome (ARDS)) will be randomized 2:1 to diaphragm neurostimulation-assisted ventilation (DNAV) using the AeroNova System plus lung-protective ventilation (Treatment) vs. lung-protective ventilation alone (Control).

03

Conditions studied

  • ARDS (Moderate or Severe)
  • AHRF
  • Mechanically Ventilated ICU Patients
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Male or female, 18 years or older, and
  2. Able to provide or have a legally authorized representative (LAR) / Substitute Decision Maker (SDM) who can provide consent, and
  3. Have acute onset of new respiratory symptoms or dysfunction within the 2 weeks before onset of need for respiratory support, and
  4. Have arterial hypoxemia defined by one of:

    • PaO2:FiO2 ratio ≤300 mm Hg on PEEP ≥5 cm H2O, or
    • In the absence of an available arterial blood gas, SpO2 ≤97% on FiO2 ≥0.5 and PEEP ≥5 cm H2O with reliable SpO2 trace for the 2 hours immediately preceding eligibility assessment (this correlates to an upper limit of SpO2:FiO2 ratio of 316%) or
    • Are receiving pulmonary vasodilators for acute hypoxemia, or
    • Are being ventilated in the prone position for acute hypoxemia, and
  5. Have been mechanically ventilated for AHRF in the ICU for \<96 hours at the time of enrolment, and
  6. Are expected to require invasive mechanical ventilation ≥48 hours after enrollment in the opinion of the treating clinician

Exclusion criteria

Exclusion Criteria:

  1. Hypoxemia is primarily attributable to acute exacerbation of , status asthmaticus, cardiogenic pulmonary edema, or pulmonary embolism.
  2. Underlying chronic parenchymal lung disease that may make recovery/extubation a challenge (e.g., COPD, pulmonary fibrosis).
  3. Broncho-pleural fistula at the time of eligibility assessment.
  4. Require extracorporeal membrane oxygenation.
  5. Pre-existing neurological, neuromuscular or muscular disorder or known phrenic nerve injury that could affect the respiratory muscles.
  6. >70 kg/m2.
  7. to left internal jugular vein or left subclavian vein catheterization (e.g., infection at the access site, known central venous stenosis, septic thrombophlebitis, left internal jugular ECMO cannula in situ, poor target vessels).
  8. Patient expected to transition to fully palliative care within 72 hours of enrollment.
  9. Chronic severe liver disease (e.g., Score ≥10)
  10. Treating clinician deems enrollment not clinically appropriate.
  11. Currently enrolled in any other study of an drug or device, which may affect the outcomes of the current study.
  12. Any electrical device (implanted or external) that may be prone to interaction with or interference from the AeroNova System, including neurological pacing/stimulator devices and cardiac pacemakers and defibrillators.
  13. Known or suspected to be pregnant or lactating.
Terms in these criteria, in plain language(6)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

COPD

Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

Child-Pugh class

A score of how well the liver works in people with liver disease such as cirrhosis: class A is mild, B moderate and C severe.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
30 participants (estimated)

Study arms

  • Experimental
    Treatment

    Treatment group subjects will have the Catheter placed percutaneously into the left jugular vein or left subclavian vein. Mapping will identify the electrodes that stimulate the phrenic nerves and enable diaphragm contraction using the AeroNova Console. The stimulation level will be titrated to target a level of diaphragm activation equivalent to resting quiet breathing by adjusting the stimulation frequency and amplitude. Subjects will receive continuous stimulation plus standard of care lung-protective ventilation.

    Device: Phrenic Nerve Stimulation

  • No intervention
    Control

    Standard of Care - Lung-protective ventilation

Interventions

  • DevicePhrenic Nerve Stimulation

    During controlled MV when patients are not breathing, continuous diaphragm neurostimulation-assisted ventilation (DNAV) will be delivered in synchrony with each ventilator-delivered breath.

    Also known as: Diaphragm neurostimulation-assisted ventilation (DNAV)

06

What researchers measure

Primary outcomes

  1. Successful device insertion, mapping, and initiation of stimulation within 18 hours of meeting readiness-to-stimulate criteria

    Time frame: Within 18 hours of meeting readiness to stimulate criteria

  2. Stimulation delivered on >50% of ventilator-triggered breaths (ascertained from continuous recordings stored in the Console)

    Time frame: 30 days

  3. Rehabilitation sessions delivered at least once per day on >50% of days when the patient was breathing in assisted (patient-triggered) mechanical ventilation

    Time frame: 30 days

Secondary outcomes

  1. Unanticipated serious adverse device events (USADE) and incidence of device- or procedure-related SAEs in the Treatment group

    Time frame: 30 days

07

Study locations

7 of 7 sites recruiting
  • University of California San Diego
    La Jolla, California 92037, United States
    Recruiting
    • Kenneth Chen, MD · Principal investigator
  • Louisiana State University Health Sciences
    Shreveport, Louisiana 71103, United States
    Recruiting
    • Jonathan Eaton, MD · Principal investigator
  • Wake Forest University School of Medicine
    Winston-Salem, North Carolina 27157, United States
    Enrolling by invitation
  • Cleveland Clinic
    Cleveland, Ohio 44195, United States
    Recruiting
    • Eduardo Mireles-Cabodevila, MD · Principal investigator
  • Temple University
    Philadelphia, Pennsylvania 19122, United States
    Recruiting
    • Gerard Criner, MD · Principal investigator
  • Prisma Health
    Columbia, South Carolina 29203, United States
    Recruiting
    • Matthew Varner, DO · Principal investigator
  • University Health Network (UHN)
    Toronto, Ontario M5G 2C4, Canada
    Recruiting
    • Ewan Goligher, MD · Principal investigator
08

References and documents

Individual participant data

Plan to share: Yes

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started May 2025 (actual). Primary completion is estimated for Sep 2026, 16 months after the start.

Of 167 interventional studies with no phase under Lymphoma, Follicular, half reached primary completion within 27 months of starting (the median), counting those still running; a quarter within 13 and three quarters within 47. This study's planned 16 months is below that.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 6, 2025
First posted
Feb 18, 2025
StartActual
May 28, 2025
Primary completionEst.
Sep 30, 2026
CompletionEst.
Mar 31, 2027
Last update
Aug 6, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 6, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06832306
Lead sponsor
Lungpacer Medical Inc.
Responsible party
Sponsor
First posted
Feb 18, 2025
Start date
May 28, 2025
Primary completion
Sep 30, 2026 (estimated)
Completion
Mar 31, 2027 (estimated)
Last update
Aug 6, 2026

Study contacts

Megan Cotts
Contact
mcotts@lungpacer.com
(612) 986-7172
STARI Study
Contact
STARIstudy@lungpacer.com
(484) 350-4530
Ewan Goligher, MD, PhD, FRCPC
principal investigator · Toronto General Hospital

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
Yes
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion